Cystoid Macular Edema in Bietti's Crystalline Retinopathy

Saatçi, Ali Osman; Doruk, Hasan Can; Yaman, Aylın

doi:10.1155/2014/964892

Cited by 10 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bietti crystalline dystrophy can be associated with other sight-threatening complications, including cystoid macular edema, choroidal neovascularization, and macular hole. [13][14][15][16][17][18][19][20][21] Fluorescein and Indocyanine Green Angiography Findings Fluorescein angiography changes correlate well with clinical findings and progression in BCD. 12,22,23 In the early stage of BCD, hyperfluorescence due to window defects appears in areas of RPE atrophy with intact choriocapillaris.…”

Section: Fundus and Anterior Segment Features Of Bcdmentioning

confidence: 74%

Genetics of Bietti Crystalline Dystrophy

Ng¹,

Lai²,

Ng³

et al. 2016

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

Bietti crystalline dystrophy (BCD) is an inherited retinal degenerative disease characterized by crystalline deposits in the retina, followed by progressive atrophy of the retinal pigment epithelium (RPE), choriocapillaris, and photoreceptors. CYP4V2 has been identified as the causative gene for BCD. The CYP4V2 gene belongs to the cytochrome P450 superfamily and encodes for fatty acid ω-hydroxylase of both saturated and unsaturated fatty acids. The CYP4V2 protein is localized most abundantly within the endoplasmic reticulum in the RPE and is postulated to play a role in the physiological lipid recycling system between the RPE and photoreceptors to maintain visual function. Electroretinographic assessments have revealed progressive dysfunction of rod and cone photoreceptors in patients with BCD. Several genotypes have been associated with more severe phenotypes based on clinical and electrophysiological findings. With the advent of multimodal imaging with spectral domain optical coherence tomography, fundus autofluorescence, and adaptive optics scanning laser ophthalmoscopy, more precise delineation of BCD severity and progression is now possible, allowing for the potential future development of targets for gene therapy.

show abstract

Section: Fundus and Anterior Segment Features Of Bcdmentioning

confidence: 74%

Genetics of Bietti Crystalline Dystrophy

Ng¹,

Lai²,

Ng³

et al. 2016

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Though the clinical features of BCD are well known SD-OCT reveals additional morphologic findings. Some of the previously reported macular changes are subretinal neovascularization [ 12 – 15 ], macular hole [ 16 ], cystoid macular edema [ 10 , 17 ], and subfoveal sensorial retinal detachment [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

“… CMT: central macular thickness, SCT: subfoveal choroidal thickness, VMA: vitreomacular adhesion, VMT: vitreomacular traction, and ORT: outer retinal tabulation. * Patient number 1 had also bilateral cystoid macular edema [ 10 ]. …”

Section: Figurementioning

confidence: 99%

Spectral Domain Optical Coherence Tomographic Findings of Bietti Crystalline Dystrophy

Saatçi

Doruk

Yaman

et al. 2014

Journal of Ophthalmology

Self Cite

View full text Add to dashboard Cite

We analyzed the OCT features of 24 eyes of 12 patients with Bietti crystalline dystrophy (BCD) with the Heidelberg HRA2-OCT. Seventeen of 24 eyes were in intermediate stage of the disease and seven in advanced stage of the disease at the time of latest OCT examination performed in 2014. Outer retinal tubulations and retinal hyperreflective dots were present in 20 of 24 eyes. The remaining four eyes had advanced disease with very thin retina. Appearance of bright plaque on top of RPE-Bruch membrane was present in all eyes. Choroidal hyperreflective spots were noted in 19 of 24 eyes. The remaining five eyes had advanced disease stage with very thin choroid. Mean central macular thickness was 163.08 μm ± 62.52 for all eyes (170.35 μm ± 56.46 in eyes with intermediate disease and 145.42 μm ± 77.2 in eyes with advanced disease). Mean subfoveal choroidal thickness was 95.37 μm ± 55.93 for the study eyes (116.47 ± 46.92 μm in eyes with intermediate disease and 44.14 μm ± 42.43 in eyes with advanced disease). Choroidal hyperreflective spots were noted in 21 of 24 eyes (87.5%). SD-OCT shows the disease progression in retinal and choroidal layers delicately in eyes with BCD and expands our knowledge about the ongoing disease process.

show abstract

“…Rare macular complications previously reported in patients with BCD include macular hole, 4 , 5 , 6 , 7 cystoid macular edema, 8 subfoveal neurosensorial detachment, 9 and macular neovascular membrane. 10 , 11 , 12 …”

Section: Introductionmentioning

confidence: 94%

Asymptomatic Unilateral Full-Thickness Macular Hole in a Patient with Bietti Crystalline Dystrophy During 13-Year Follow-up with Optical Coherence Tomography

Saatçi

Kayabaşı

Avcı

2022

tjo

Self Cite

View full text Add to dashboard Cite

A 39-year-old woman with progressive bilateral visual decline was diagnosed as having Bietti crystalline dystrophy in 2008. The disease course was monitored with optical coherence tomography until 2021. During the last routine eye examination in 2021, a full-thickness, slightly eccentric, visually asymptomatic macular hole with an intact foveola was noted in the left eye. No surgical treatment was recommended. The pathogenesis of full-thickness macular hole remained unclear as there were only subtle signs of prior very mild macular edema and vitreomacular interface abnormality. A degenerative process was also possible.

show abstract

Cystoid Macular Edema in Bietti's Crystalline Retinopathy

Cited by 10 publications

References 21 publications

Genetics of Bietti Crystalline Dystrophy

Genetics of Bietti Crystalline Dystrophy

Spectral Domain Optical Coherence Tomographic Findings of Bietti Crystalline Dystrophy

Asymptomatic Unilateral Full-Thickness Macular Hole in a Patient with Bietti Crystalline Dystrophy During 13-Year Follow-up with Optical Coherence Tomography

Contact Info

Product

Resources

About